Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Addition of Pembrolizumab to Radiation Treatment for Newly Diagnosed Early Stage MSI-High Endometrial Cancer
Addition of Pembrolizumab to Radiation Treatment for Newly Diagnosed Early Stage MSI-High Endometrial Cancer

Addition of Pembrolizumab to Radiation Treatment for Newly Diagnosed Early Stage MSI-High Endometrial Cancer

Clinicaltrials.gov identifier:
NCT04214067


Study Contact Information:

Principal Investigator: Floor Backes    

For additional information: Use the contacts listed per each study location. 


Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

About the Study

The purpose of this study is to determine whether the addition of the agent, pembrolizumab (Keytruda) to radiation therapy is more effective than radiation therapy alone in reducing the risk of cancer recurrence in patients with newly diagnosed I-II endometrial cancer that is . NOTE: This study is no longer enrolling. 

 

This Study is Open To:

This study is no longer enrolling.

This Study is Not Open To:
  • This study is no longer enrolling.